- Published on
Toxicology: Teratogens
BASICS
DESCRIPTION
A teratogen is a substance, environmental exposure, or maternal condition capable of producing permanent structural or functional abnormalities in a developing fetus during pregnancy. Traditionally, this definition excludes agents that solely cause fetal death or interfere with fetal growth without producing lasting abnormalities.
Teratogenic factors may include medications, industrial chemicals, infectious organisms, physical exposures, and nutritional deficiencies.
The terms anomaly and malformation generally describe abnormalities in anatomical structure. A congenital or birth defect may involve morphological, biochemical, enzymatic, genetic, or chromosomal alterations present at birth.
A syndrome refers to a recognizable combination of abnormalities that occur together and may be associated with a particular genetic condition, environmental exposure, or teratogenic agent.
PATHOPHYSIOLOGY
Teratogenic agents may interfere with normal fetal development through several biological mechanisms.
Chromosomal disruption: Damage to chromosomal integrity or interference with normal DNA replication may alter cellular growth and differentiation.
Hormonal disturbances: Changes in the fetal hormonal environment may disrupt sexual differentiation and organ development.
Nutritional or oxygen deprivation: Reduced availability of essential nutrients or oxygen may impair normal embryonic and fetal development.
Accumulation within developing tissues: Certain chemicals or their metabolites may become deposited in fetal tissues, interfering with cellular development and organ formation.
EPIDEMIOLOGY
Approximately 3% of newborn infants are identified as having a congenital abnormality at birth.
As children grow and additional developmental or structural abnormalities are recognized, the cumulative proportion of individuals diagnosed with congenital defects may approach 6%.
Congenital abnormalities are encountered more frequently among premature infants, stillborn infants, and embryos or fetuses lost through spontaneous pregnancy termination.
PREGNANCY AND LACTATION
Historical United States FDA Pregnancy Risk Categories
The former US Food and Drug Administration pregnancy classification system divided medications into five categories according to available evidence concerning potential fetal harm.
Category A: Adequately controlled studies involving pregnant women did not demonstrate an increased risk of fetal abnormalities during the first trimester. The likelihood of fetal injury was considered minimal.
Category B: Animal reproductive studies did not identify fetal harm, although adequate controlled studies in pregnant women were unavailable. Alternatively, adverse fetal effects observed in animals were not confirmed in well-controlled human studies.
Category C: Animal investigations demonstrated embryotoxic or teratogenic effects, but sufficient controlled human studies were lacking. This category also included medications for which reproductive safety information was unavailable in both animals and humans.
Category D: Evidence indicated a potential risk to the human fetus. Nevertheless, treatment could be considered when maternal benefits outweighed fetal risks, particularly in severe or life-threatening conditions where safer alternatives were unavailable or ineffective.
Category X: Human or animal evidence demonstrated fetal abnormalities or significant reproductive harm, and the potential risks were considered greater than any anticipated therapeutic benefit during pregnancy.
Important: These A, B, C, D, and X categories are historical. The FDA replaced this system with narrative pregnancy and lactation labeling under the Pregnancy and Lactation Labeling Rule, which took effect in 2015.
DIAGNOSIS
DIFFERENTIAL DIAGNOSIS
KNOWN TERATOGENS
Androgenic Hormones
Androgenic medications, including testosterone, methyltestosterone, norethindrone-related androgenic preparations, danazol, and other synthetic androgens, may interfere with normal sexual differentiation in female fetuses.
Exposure during approximately the first 90 days of pregnancy has been associated with masculinization of external genital structures, including enlargement of the clitoris and fusion of the labia.
Anticoagulants
Warfarin and related coumarin anticoagulants can cross the placenta and cause fetal abnormalities.
Historical reports described pregnancy loss or stillbirth in approximately one-sixth of exposed pregnancies, with fetal malformations occurring in another one-sixth. These figures represent older observations rather than universal estimates of risk.
Exposure during the first 100 days of gestation has been associated with nasal hypoplasia, reduced birth size, and skeletal abnormalities characterized by punctate calcification of developing epiphyses, commonly known as chondrodysplasia punctata.
Exposure later in pregnancy may result in neurological and ocular abnormalities, including hydrocephalus, visual impairment, and developmental or intellectual disability.
Antineoplastic Agents
Several antineoplastic medications have demonstrated teratogenic potential, including azauridine, bleomycin, busulfan, chlorambucil, cisplatin, fluorouracil, hydroxyurea, mechlorethamine, melphalan, and methotrexate.
Prenatal exposure to certain cytotoxic agents may produce abnormalities affecting multiple organ systems. Historical reports described congenital anomaly rates ranging from approximately 10% to 50%, although the actual risk differs considerably according to the specific drug, dose, and gestational period.
Folate supplementation has historically been discussed in relation to exposure to antifolate agents such as methotrexate. However, supplementation does not eliminate the reproductive risks associated with methotrexate exposure.
Carbamazepine
Prenatal carbamazepine exposure has been associated with an increased risk of neural tube defects, with older estimates suggesting a risk of approximately 1%.
Maternal folic acid supplementation is generally considered important for individuals taking antiseizure medications who are planning pregnancy or are pregnant, with the dose determined by clinical guidance.
Carbon Monoxide
Maternal carbon monoxide poisoning can interfere with fetal oxygen delivery and cause significant neurological injury.
Reported complications include cerebral atrophy, microcephaly, seizures, cerebral palsy, developmental and intellectual impairment, and an increased likelihood of fetal loss.
Diethylstilbestrol (DES)
Prenatal exposure to diethylstilbestrol, particularly before the eighteenth week of pregnancy, has been associated with an increased risk of clear-cell adenocarcinoma involving the vagina or cervix in exposed female offspring.
Additional reproductive complications reported among exposed daughters include menstrual irregularities, reduced fertility, spontaneous pregnancy loss, premature delivery, and increased perinatal complications.
Male offspring exposed before birth have also demonstrated reproductive tract abnormalities and alterations in sperm characteristics.
Ethanol
Prolonged maternal alcohol consumption during pregnancy may produce fetal alcohol syndrome and other disorders within the fetal alcohol spectrum.
Typical manifestations include impaired fetal growth, neurological and neurodevelopmental abnormalities, and distinctive craniofacial findings such as microcephaly, maxillary hypoplasia, cleft palate, and micrognathia.
Older clinical reports involving chronic maternal alcohol exposure described perinatal mortality rates of approximately 17% and intellectual impairment in up to 44% of offspring. These historical figures should not be interpreted as current population-wide risk estimates.
Iodine and Antithyroid Medications
Excessive iodine exposure and maternal treatment with antithyroid medications, including methimazole and propylthiouracil, may affect fetal thyroid function.
Potential consequences include fetal or neonatal thyroid enlargement and hypothyroidism, particularly when clinically significant exposure occurs during later pregnancy.
Severe untreated congenital hypothyroidism may lead to permanent neurological and developmental impairment.
Isotretinoin and Related Retinoids
Systemic retinoids, including isotretinoin and etretinate, are associated with a substantial risk of fetal malformations.
Reported abnormalities include craniofacial defects, congenital cardiac malformations, hydrocephalus, microcephaly, and central nervous system developmental abnormalities.
Historical estimates suggested that fetal abnormalities occurred in approximately 38% of certain exposed pregnancies, with neurological abnormalities predominating in some reports.
The actual risk depends on the specific retinoid, timing of exposure, and pregnancy outcome.
Lead
Elevated maternal blood lead concentrations have been associated with poorer performance on developmental assessments among exposed children.
Prenatal lead exposure may increase the risk of neurodevelopmental delay and impairment in cognitive functioning.
Earlier studies identified maternal blood lead concentrations above 10 micrograms per deciliter (µg/dL) as a level of concern. Current understanding recognizes that no blood lead concentration has been established as safe during pregnancy.
Lithium
Maternal lithium exposure has been associated with an increased risk of congenital cardiac abnormalities, including Ebstein anomaly, a malformation involving the tricuspid valve.
The magnitude of risk should be interpreted using current evidence because older studies may have overestimated the association.
Mercury
Prenatal exposure to toxic forms of mercury may damage the developing nervous system and other fetal organs.
Reported manifestations include cerebral palsy, intellectual and developmental impairment, microcephaly, ocular abnormalities, and dental malocclusion.
Historical descriptions identified exposure during the sixth through eighth months of gestation as particularly concerning, although susceptibility varies with mercury species, exposure intensity, and developmental timing.
Methimazole
Methimazole exposure during pregnancy has been associated with characteristic congenital abnormalities, including localized defects of the scalp known as aplasia cutis congenita.
Several clinical reports have described this association, particularly following exposure during early fetal development.
D-Penicillamine
Prenatal exposure to D-penicillamine has been associated with connective tissue abnormalities, including excessive skin elasticity and laxity.
These findings have been described in association with disturbances in normal connective tissue development.
Phenytoin
Maternal phenytoin use may result in a recognizable pattern of abnormalities referred to as fetal hydantoin syndrome.
Clinical characteristics include a depressed nasal bridge, hypertelorism, abnormal external ears, underdevelopment of the digits, skeletal malformations, microcephaly, growth restriction, and neurodevelopmental impairment.
Congenital cardiac abnormalities and other less consistently established associations, including neuroblastoma, have also been described.
Older studies estimated that approximately 11% of exposed offspring developed the complete syndrome, while another 31% displayed partial features. These estimates vary across studies and should be regarded as historical.
Polychlorinated Biphenyls (PCBs)
Maternal exposure to polychlorinated biphenyls has been associated with fetal growth impairment and developmental abnormalities.
An incident involving PCB-contaminated rice oil produced a characteristic pattern of neonatal skin hyperpigmentation historically described as the “cola-colored baby” syndrome.
Other reported findings included intrauterine growth restriction, ocular abnormalities, and teeth present at birth.
Thalidomide
Thalidomide is a well-established human teratogen associated with severe limb and organ malformations.
Exposure during the critical embryonic developmental period, historically described as days 21–40 after conception, may produce phocomelia, characterized by severe shortening or absence of limb segments.
Additional abnormalities may involve facial structures, the gastrointestinal tract, the heart, and the kidneys.
Historical estimates indicated that approximately 20% of pregnancies exposed during the most vulnerable developmental period resulted in characteristic congenital malformations.
Tetracyclines
Tetracycline antibiotics, including doxycycline, have historically been associated with discoloration of developing fetal teeth.
Older reports suggested that exposure after approximately 120 days of gestation could affect primary tooth pigmentation, with discoloration described in up to half of certain exposed cases.
Exposure later in gestation was also considered capable of affecting developing permanent teeth, whereas early exposure before tooth mineralization was not associated with the same staining effects.
Risks differ among individual tetracycline antibiotics, and current evidence does not support treating all tetracyclines as having identical fetal effects.
Trimethadione and Paramethadione
Prenatal exposure to trimethadione or paramethadione has been associated with a characteristic constellation of congenital abnormalities.
Reported findings include intellectual impairment, V-shaped eyebrows, epicanthal folds, low-set ears with folded helices, intrauterine growth restriction, palatal defects, congenital cardiac abnormalities, and irregular dentition.
Valproate
Valproate exposure during pregnancy is associated with an increased risk of neural tube defects and other structural and neurodevelopmental abnormalities.
The historical source estimated the risk of neural tube defects at approximately 1.2%.
Other reported abnormalities include microcephaly and congenital cardiac defects. Subsequent evidence has further established important developmental risks associated with prenatal valproate exposure.
POSSIBLE TERATOGENS AND OTHER PRENATAL TOXIC EXPOSURES
Aminoglycosides
Aminoglycoside antibiotics, including gentamicin, kanamycin, streptomycin, and tobramycin, have been investigated for possible fetal ototoxicity.
Hearing impairment has been reported following maternal exposure to certain aminoglycosides. The risk varies among individual agents and exposure circumstances.
Angiotensin-Converting Enzyme (ACE) Inhibitors
Medications such as captopril, enalapril, lisinopril, and ramipril can cause significant fetal toxicity, especially when exposure occurs during the second or third trimester.
Potential complications include impaired renal development and function, intrauterine growth restriction, reduced skull ossification, pulmonary hypoplasia, and neonatal hypotension.
Barbiturates
Barbiturate medications include amobarbital, butabarbital, methohexital, pentobarbital, phenobarbital, primidone, secobarbital, and thiopental.
Several congenital abnormalities have been reported following prenatal exposure to these agents. However, findings across studies have been inconsistent, making it difficult to establish a uniform teratogenic effect for the entire drug class.
Benzodiazepines
Diazepam exposure during the first trimester has produced increased fetal mortality and thoracic vertebral abnormalities in certain animal studies.
Human investigations have not consistently demonstrated a comparable pattern of congenital malformations.
Risk assessment should distinguish structural teratogenicity from other possible neonatal effects associated with medication exposure.
Bromides
Prenatal bromide exposure has historically been linked to skeletal and gastrointestinal abnormalities.
Maternal exposure close to delivery has also been associated with neonatal hypotonia and central nervous system depression, which were reported to resolve after the exposure ended.
Chenodiol
Animal reproductive studies involving chenodiol identified fetal liver toxicity and tissue necrosis affecting the adrenal glands and kidneys.
The relevance of these findings to human pregnancy requires cautious interpretation.
Cigarette Smoking
Maternal cigarette smoking is associated with several adverse pregnancy outcomes, including fetal growth restriction, placental abruption, placenta previa, and placental abnormalities that may compromise uteroplacental circulation.
Smoking during pregnancy has also been linked to increased perinatal mortality and a higher risk of sudden infant death syndrome.
These effects are primarily associated with impaired fetal growth, placental dysfunction, and adverse developmental outcomes rather than a single characteristic malformation syndrome.
Cocaine
Cocaine exposure during pregnancy has been associated with premature delivery, spontaneous pregnancy loss, placental abruption, and impaired fetal growth.
Some reports have described congenital abnormalities involving the genitourinary system, heart, face, and extremities.
Neonatal neurobehavioral and neurophysiological disturbances have also been reported, although the contribution of other maternal and environmental factors must be considered.
Colchicine
Human studies involving maternal colchicine treatment, including its use for gout and other inflammatory disorders, have not consistently demonstrated an increased risk of congenital malformations.
Teratogenic findings have nevertheless been reported in experimental animals.
Paternal colchicine exposure has also been associated in some reports with impaired sperm production, including azoospermia.
Corticosteroids
Systemic corticosteroids include cortisone, dexamethasone, hydrocortisone, methylprednisolone, prednisolone, prednisone, and triamcinolone.
Various congenital abnormalities have been reported following maternal corticosteroid exposure. However, the historical literature did not establish a consistent causal relationship between therapeutic corticosteroid use and congenital malformations.
Interpretation requires consideration of the particular medication, dose, timing, and underlying maternal illness.
Diuretics
Common diuretic medications include chlorothiazide, hydrochlorothiazide, furosemide, and triamterene.
Experimental animal studies have associated high-dose loop diuretic exposure with certain fetal abnormalities, but comparable structural risks have not been consistently demonstrated in humans.
Some historical reports suggested a possible increase in congenital abnormalities following first-trimester thiazide exposure, although this association has not been firmly established.
Ergot Alkaloids
Ergot-derived medications include dihydroergotamine, ergonovine, ergotamine, and methylergonovine.
The historical literature did not consistently identify congenital malformations following limited exposure. Nevertheless, these agents may produce important maternal and fetal effects through their vasoconstrictive and uterotonic properties.
Estrogenic Hormones
Estrogen-containing preparations, including estradiol, ethinyl estradiol, and mestranol, have been investigated for possible associations with fetal malformations.
Available historical studies did not consistently demonstrate an increased incidence of congenital abnormalities following exposure.
Marijuana
Maternal cannabis exposure has been investigated as a possible contributor to impaired fetal growth.
Some studies have reported associations with reduced birth weight and other adverse pregnancy outcomes, although interpretation may be influenced by concurrent exposures and maternal health factors.
Mifepristone
Mifepristone, previously identified by the developmental code RU-486, has been evaluated for potential developmental toxicity.
The historical source noted limited human pregnancy outcome data and inconsistent findings across animal species, with teratogenic effects reported in some experimental models but not others.
These older findings should not be interpreted as a definitive estimate of congenital anomaly risk in ongoing human pregnancies.
Minoxidil
Prenatal exposure to minoxidil has been associated in case reports with neonatal hypertrichosis, characterized by excessive hair growth.
This finding may reflect the pharmacological effect of minoxidil on hair follicles.
Oral Contraceptives
Inadvertent exposure to oral contraceptives during early pregnancy has not been conclusively linked to an increased incidence of major congenital abnormalities.
Historical investigations did not establish a consistent pattern of malformations attributable to these medications.
Phencyclidine
Prenatal phencyclidine exposure has been associated with neurological and behavioral disturbances in newborn infants.
Reported features include irritability, increased muscle tone, poor feeding, ineffective sucking, nystagmus, inadequate head control, respiratory distress, and certain facial abnormalities.
Progestational Hormones
Progestational agents include ethynodiol, levonorgestrel, norethindrone, and norgestrel.
Older investigations did not consistently demonstrate an increased frequency of congenital abnormalities following prenatal exposure.
Historical reports suggested a small risk, estimated at approximately 0.3%, of masculinization of female fetuses following exposure to certain hormonal preparations. This estimate should not be generalized to contemporary progestin medications.
Rifampin
Maternal rifampin therapy has been associated with concerns regarding altered vitamin K-dependent coagulation, particularly when exposure occurs close to delivery.
Potential complications include neonatal hypoprothrombinemia and an increased tendency toward bleeding.
Quinine
Therapeutic quinine exposure for malaria has not been conclusively demonstrated to increase congenital malformations when used at appropriate doses.
The fetal risks associated with malaria itself must also be considered when evaluating treatment during pregnancy.
Ribavirin
Ribavirin has demonstrated significant teratogenic and embryotoxic effects in animal reproductive studies.
The historical literature noted limited human pregnancy data but reported developmental toxicity across the animal species examined.
Because of these findings, pregnancy exposure to ribavirin requires careful specialist assessment.
Organic Solvents
Exposure to certain industrial and environmental solvents has been investigated in relation to congenital developmental abnormalities.
Historical reports have described associations between maternal solvent exposure and intestinal atresia, although the degree of risk depends on the specific chemical and circumstances of exposure.
Sulfonylureas
Sulfonylurea medications include acetohexamide, chlorpropamide, glipizide, glyburide, and tolbutamide.
Maternal use of certain oral hypoglycemic agents close to delivery has been associated with persistent neonatal hypoglycemia.
This complication is related to altered fetal or neonatal glucose regulation and should be distinguished from structural teratogenicity.
Tricyclic Antidepressants
Tricyclic antidepressants include amitriptyline, doxepin, imipramine, desipramine, and nortriptyline.
Case reports have described limb reduction defects and other congenital abnormalities following maternal exposure, particularly with amitriptyline.
However, broader studies have not consistently demonstrated a major teratogenic effect attributable to this medication class.
Assessment of treatment during pregnancy should consider the specific drug, maternal psychiatric condition, and available reproductive safety evidence.
Vaccines and Maternal Infections
Certain maternal infections can cause fetal abnormalities or increase the likelihood of pregnancy loss.
Historical discussions identified maternal measles infection as a possible contributor to adverse pregnancy outcomes, including spontaneous abortion and reported congenital abnormalities.
Concerns were also expressed regarding the administration of certain live vaccines during pregnancy, based partly on theoretical fetal risks associated with live infectious agents.
These historical statements should not be interpreted as evidence that all vaccines are teratogenic. Current pregnancy immunization guidance distinguishes vaccines that are recommended during pregnancy from live vaccines that are generally avoided.
PROCEDURES AND LABORATORY TESTS
Pregnancy Testing
Pregnancy status should be assessed in patients with reproductive potential following exposure to a suspected teratogenic substance when the result may influence medical management.
The historical guidance recommended pregnancy testing for female patients between approximately 10 and 45 years of age following potentially teratogenic exposure.
In contemporary practice, testing should be guided by individual reproductive potential, clinical circumstances, informed consent, and the relevance of pregnancy status to the treatment plan.
TREATMENT
The fundamental objective of managing teratogenic exposure is to preserve maternal health while minimizing potential harm to the developing fetus.
Appropriate maternal medical care, early recognition of harmful exposures, and timely treatment of underlying conditions are important factors in improving fetal outcomes.
When a pregnant patient has been exposed to a known or suspected teratogen, referral to an obstetric specialist is recommended for individualized risk assessment and pregnancy surveillance.
Depending on the substance involved, gestational age, and exposure severity, the obstetric team may recommend targeted ultrasonography, evaluation of fetal anatomy and growth, additional diagnostic testing, or consultation with maternal-fetal medicine and clinical toxicology specialists.
Counseling should consider the specific substance, duration and intensity of exposure, timing during fetal development, and available evidence concerning possible adverse outcomes.
ICD-9-CM CLASSIFICATION
760.0–779.9 — Historical classification range covering conditions originating during the perinatal period, including certain disorders and complications affecting fetuses and newborn infants.
Drug-related complications and poisoning affecting newborn infants were included within this broader historical coding framework.